: Frequently cited as a top "marijuana" buy due to its FDA-track medical developments, though not a traditional penny stock.
: Gained 40.6% in a single month (August 2017) and remained a top growth pick for Canadian exposure.
Many of the current industry giants were once considered penny or low-priced stocks during this period:
: Gained 7,100% in the first half of the year, reaching $0.18.
: Frequently cited as a top "marijuana" buy due to its FDA-track medical developments, though not a traditional penny stock.
: Gained 40.6% in a single month (August 2017) and remained a top growth pick for Canadian exposure.
Many of the current industry giants were once considered penny or low-priced stocks during this period:
: Gained 7,100% in the first half of the year, reaching $0.18.